Eczema drug restores hair growth in patient with longstanding alopecia

October 10, 2018, Massachusetts General Hospital
Fine light hairs called vellus hairs appear on the scalp of a patient with alopecia totalis six weeks after she began dupilumab treatment for eczema. Credit: JAMA Network.

Massachusetts General Hospital (MGH) physicians are reporting an unexpected side-effect from treatment with dupilumab, which is FDA approved for the treatment of moderate to severe eczema, also called atopic dermatitis. In their case report published in JAMA Dermatology, the physicians describe how their 13-year-old patient, who has alopecia totalis—a total lack of scalp hair—along with eczema, experienced significant hair regrowth while being treated with dupilumab, a drug marketed under the brand name Dupixent.

"We were quite surprised since this patient hadn't grown scalp since the age of 2, and other treatments that can help with hair loss did not in her case," says Maryanne Makredes Senna, MD, of the MGH Department of Dermatology, senior author of the JAMA Dermatology report. "As far as we know, this is the first report of hair regrowth with dupilumab in a patient with any degree of alopecia areata."

In addition to longstanding alopecia, this patient had experienced extensive, -resistant eczema since the age of 7 months. Treatment with prednisone and methotrexate, medications that can suppress the overactive immune system, led to limited improvement in the patient's eczema but no and was therefore discontinued. In July 2017 she began to be treated with weekly injections of dupilumab, which had recently received FDA approval. After six weeks of treatment, which led to significant improvement in eczema symptoms, she also noticed that fine light hairs called vellus hairs were appearing on her scalp.

After 11 months of dupilumab treatment, significant pigmented hair has grown across the patient's scalp. Credit: JAMA Network

After seven months of dupilumab treatment, the patient had grown a significant amount of the pigmented hair that typically grows on the scalp. Because of a change in her insurance coverage, she had to discontinue dupilumab for a two-month period, during which she noticed shedding of the recently regrown hair. But after she could resume treatment in April 2018, the hair growth resumed and has continued.

Senna explains that dupilumab's mechanism of targeting a key immune system pathway known to be overactive in eczema could explain its action against alopecia, since recent studies have suggested other elements of the same pathway may induce autoimmune . "Right now, it's hard to know whether dupilumab could induce hair growth in other alopecia , but I suspect it may be helpful in patients with extensive active and active areata," she says. "We've submitted a proposal for a clinical trial using dupilumab in this patient population and hope to be able to investigate it further in the near future." Senna is the principal investigator of the Hair Academic Innovative Research (HAIR) clinical research unit at MGH and an instructor in Dermatology at Harvard Medical School.

Explore further: Baldness caused by alopecia could soon be treatable

More information: JAMA Dermatology (2018). DOI: 10.1001/jamadermatol.2018.29

Related Stories

Baldness caused by alopecia could soon be treatable

September 17, 2018
Baldness caused by alopecia areata could soon be treated safely and effectively, after an international University of Melbourne-led trial found two new drugs to be safe and effective.

Doctors help teen girl with alopecia areata grow hair using novel cream

December 10, 2015
A young woman who had no scalp or eyebrow hair for years now enjoys a full mane after using a novel cream devised by researchers at Yale School of Medicine.

UVA-1 promising for patients with refractory alopecia areata

September 28, 2015
(HealthDay)—For patients with alopecia areata (AA), phototherapy with ultraviolet A-1 (UVA-1) is a promising treatment modality, according to a research letter published in the October issue of the International Journal ...

In hairless man, arthritis drug spurs hair growth—lots

June 19, 2014
A man with almost no hair on his body has grown a full head of it after a novel treatment by doctors at Yale University.

Simvastatin / ezetimibe not beneficial in alopecia areata

April 27, 2016
(HealthDay)—Simvastatin/ezetimibe does not appear to be beneficial for severe alopecia areata (AA) in a sample of 20 patients, according to a letter to the editor published in the May issue of the Journal of the American ...

Arthritis drug may help with type of hair loss

September 22, 2016
(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

Recommended for you

A bad influence—the interplay between tumor cells and immune cells

October 16, 2018
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ...

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Immune health maintained by meticulously ordered DNA

October 15, 2018
Walter and Eliza Hall Institute researchers have revealed how immune health is maintained by the exquisite organisation skills of a protein called Pax5.

New immunotherapy targeting blood-clotting protein

October 15, 2018
Normally, the blood protein fibrin does not enter the brain. But in several neurological disorders, the blood-brain barrier—which keeps large molecules in the blood from entering the brain—becomes abnormally permeable, ...

Enzyme that triggers autoimmune responses from T-cells in patients with MS found

October 11, 2018
A team of researchers from Switzerland, the U.S. and Spain has isolated an enzyme that triggers an autoimmune response from T-cells in patients with MS. In their paper published in the journal Science Translational Medicine, ...

Scientists reveal new cystic fibrosis treatments work best in inflamed airways

October 11, 2018
A new UNC School of Medicine study shows that two cystic fibrosis (CF) drugs aimed at correcting the defected CFTR protein seem to be more effective when a patient's airway is inflamed. This is the first study to evaluate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.